

## inhaled interferon - all results

Treatment	Number of studies	clinical deterioration	clinical improvement	deaths	viral clearance
IFN alpha	2 studies <sup>1</sup>	0.52 [0.02 ; 15.78], 1 RCT, I2=0% inconclusive result	1.28 [0.53 ; 3.09], 2 RCTs, I2=54% demonstrated inconclusive result	1.93 [0.24 ; 15.47], 3 RCTs, I2=0% inconclusive result	2.90 [1.64 ; 5.14], 3 RCTs, I2=0% moderate degree of certainty
SNG001 inhaled interferon beta	2 studies <sup>2</sup>	0.65 [0.42 ; 1.00], 2 RCTs, I2=0% inconclusive result	2.32 [1.07 ; 5.04], 1 RCT, I2=0% certainty unassessable	0.72 [0.35 ; 1.48], 2 RCTs, I2=0% inconclusive result	-
recombinant super-compound interferon rSIFN-co	1 study <sup>3</sup>	0.52 [0.02 ; 15.78], 1 RCT, I2=0% inconclusive result	1.76 [1.10 ; 2.81], 1 RCT, I2=0% demonstrated certainty unassessable	1.04 [0.02 ; 53.73], 1 RCT, I2=0% inconclusive result	7.68 [0.91 ; 65.15], 1 RCT, I2=0% inconclusive result

### Notes

<sup>1</sup>Pandit, 2021 (CTRI/2020/06/026087); Shashi Bhushan, 2021 (CTRI/2020/12/029855)

<sup>2</sup>SPRINTER, 2022 (NCT04732949); Synairgen SG016, 2020 (NCT04385095)

<sup>3</sup>Li, 2021 (ChiCTR2000029638)